MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/vaccines13020127

Медицинская библиотека · Vaccines · 2025

Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study.

Sartori Natália Sarzi, Machado Ketty Lysie Libardi Lira, Miyamoto Samira Tatiyama, Pretti Flávia Zon, Gouveia Maria da Penha Gomes, de Oliveira Yasmin Gurtler Pinheiro, da Silva Vanezia Gonçalves, Faé Filipe, Burian Ana Paula Neves, Tapia Karina Rosemarie Lallemand, Moulin Anna Carolina Simões, Grillo Luiza Lorenzoni, Athayde Paula Dos Santos, Corona Helena da Silva, Ramos Sabrina de Souza, Peixoto Flávia Maria Matos Melo Campos, Ribeiro Priscila Dias Cardoso, Magalhães Vanessa de Oliveira, de Aguiar Mariana Freitas, Biegelmeyer Erika, Kayser Cristiane, de Souza Alexandre Wagner Silva, de Moura Castro Charlles Heldan, Bühring Juliana, Ribeiro Sandra Lúcia Euzébio, Oliveira Dos Santos Sérgio Henrique, Martins Clara Pinheiro, da Silva Rodrigues Jonathan Willian, Sousa Dias Marcos Mavignier, Dutra Bruna Guimarães, Telles Camila Maria Paiva França, Basualto Dias Samuel Elias, Rezende Rodrigo Poubel Vieira de, Baptista Katia Lino, Gaudio Rodrigo Cutrim, Melo Ana Karla Guedes de, da Silva Valéria Bezerra, Cruz Vitor Alves, Rêgo Jozelia, Vieira Rejane Maria Rodrigues de Abreu, Vieira Adah Sophia Rodrigues, Kakehasi Adriana Maria, Tavares Anna Carolina Faria Moreira Gomes, Carvalho Victória Dornelas Paz, Azevedo Renata Henriques de, Azevedo Valderilio Feijó, Martins-Filho Olindo Assis, Peruhype-Magalhães Vanessa, Gasparin Andrese Aline, Hax Vanessa, Valim Valéria, Ferreira Gilda Aparecida, Teixeira-Carvalho Andréa, Reis-Neto Edgard Torres Dos, Sato Emília Inoue, Pinheiro Marcelo de Medeiros, de Souza Viviane Angelina, Xavier Ricardo Machado, Pileggi Gecilmara Salviato, Monticielo Odirlei André, SAFER-Study Group Task Force

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the humoral response to and impact of SARS-CoV-2 vaccination in patients with systemic lupus erythematosus in a multicenter cohort design.

METHODS

Data for this analysis were obtained from the Study of Safety, Effectiveness and Duration of Immunity after Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Inflammatory Diseases (SAFER), a prospective, multicenter, phase IV, real-world study conducted across different regions of Brazil from June/2021 to March/2024. Patients aged >18 years with systemic lupus erythematosus (SLE) who received any one of the SARS-CoV-2 vaccines approved by the Brazilian health regulatory agency (CoronaVac [inactivated SARS-CoV-2 vaccine], ChAdOx-1 [AstraZeneca], or BNT162b2 [Pfizer-BioNTech]) were included. Immunogenicity was assessed in pre- and post-vaccination blood samples, and patients were monitored in person and remotely for the occurrence and severity of COVID-19.

RESULTS

Two hundred and thirty-five patients with SLE who had completed their vaccination schedules (two doses + booster dose) were included in this study. Most patients were female (89.3%) and had low disease activity or were in remission (72.4%); the majority were also on some form of immunosuppressive therapy (58.1%). One hundred and sixteen patients received two doses of CoronaVac followed by one dose of BNT162b2 (Pfizer-BioNTech) vaccine, eighty-seven received two doses of ChAdOx1-S (AstraZeneca) followed by one dose of BNT162b2 (Pfizer-BioNTech) vaccine, and thirty-two received three doses of BNT162b2 (Pfizer-BioNTech) vaccine. Twenty-eight cases of COVID-19, none meeting criteria for severe COVID-19, were recorded in patients with respiratory symptoms after the second dose of a SARS-CoV-2 vaccine. Regarding immunogenicity, an increase in seroconversion rate was observed following consecutive vaccine doses, with no difference between vaccination schedules, reaching 97.57% seropositivity after a booster dose. The geometric mean IgG titers differed between the different vaccination schedules after the first and the second vaccine dose, being lowest for the CoronaVac-based schedule, but titers were similar after the administration of a booster dose.

CONCLUSION

In patients with SLE, SARS-CoV-2 vaccines are immunogenic, inducing a robust humoral response. No severe outcomes associated with death or hospitalization were found in the evaluated patient sample. Complete vaccination schedules including a booster dose induced higher humoral responses than incomplete schedules, especially in patients initially immunized with an inactivated virus vaccine schedule and those with a suboptimal humoral response.

Для цитирования: Sartori Natália Sarzi, Machado Ketty Lysie Libardi Lira, Miyamoto Samira Tatiyama, Pretti Flávia Zon, Gouveia Maria da Penha Gomes, de Oliveira Yasmin Gurtler Pinheiro, da Silva Vanezia Gonçalves, Faé Filipe, Burian Ana Paula Neves, Tapia Karina Rosemarie Lallemand, Moulin Anna Carolina Simões, Grillo Luiza Lorenzoni, Athayde Paula Dos Santos, Corona Helena da Silva, Ramos Sabrina de Souza, Peixoto Flávia Maria Matos Melo Campos, Ribeiro Priscila Dias Cardoso, Magalhães Vanessa de Oliveira, de Aguiar Mariana Freitas, Biegelmeyer Erika, Kayser Cristiane, de Souza Alexandre Wagner Silva, de Moura Castro Charlles Heldan, Bühring Juliana, Ribeiro Sandra Lúcia Euzébio, Oliveira Dos Santos Sérgio Henrique, Martins Clara Pinheiro, da Silva Rodrigues Jonathan Willian, Sousa Dias Marcos Mavignier, Dutra Bruna Guimarães, Telles Camila Maria Paiva França, Basualto Dias Samuel Elias, Rezende Rodrigo Poubel Vieira de, Baptista Katia Lino, Gaudio Rodrigo Cutrim, Melo Ana Karla Guedes de, da Silva Valéria Bezerra, Cruz Vitor Alves, Rêgo Jozelia, Vieira Rejane Maria Rodrigues de Abreu, Vieira Adah Sophia Rodrigues, Kakehasi Adriana Maria, Tavares Anna Carolina Faria Moreira Gomes, Carvalho Victória Dornelas Paz, Azevedo Renata Henriques de, Azevedo Valderilio Feijó, Martins-Filho Olindo Assis, Peruhype-Magalhães Vanessa, Gasparin Andrese Aline, Hax Vanessa, Valim Valéria, Ferreira Gilda Aparecida, Teixeira-Carvalho Andréa, Reis-Neto Edgard Torres Dos, Sato Emília Inoue, Pinheiro Marcelo de Medeiros, de Souza Viviane Angelina, Xavier Ricardo Machado, Pileggi Gecilmara Salviato, Monticielo Odirlei André, SAFER-Study Group Task Force. Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study.. Vaccines. 2025. DOI: 10.3390/vaccines13020127.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.